Cleared Traditional

K790317 - PAP RIA KIT

K790317 is an FDA 510(k) clearance for PAP RIA KIT, manufactured by Yang Laboratories, Inc.. The device is a Class 2 Chemistry device with product code JFH cleared through the Traditional 510(k) pathway after a 81-day FDA review.

Download Printable Device Report (PDF)
Optimized for regulatory review, auditing and printing
May 1979
Decision
81d
Days
Class 2
Risk

K790317 is an FDA 510(k) clearance for the PAP RIA KIT. Classified as Acid Phosphatase (prostatic), Tartrate Inhibited (product code JFH), Class II - Special Controls.

Submitted by Yang Laboratories, Inc. (Walker, US). The FDA issued a Cleared decision on May 7, 1979 after a review of 81 days - a notably fast clearance cycle.

This device falls under the Chemistry FDA review panel, regulated under 21 CFR 862.1020 - the FDA in vitro diagnostics and chemistry framework. The Traditional 510(k) pathway establishes clearance through substantial equivalence to a legally marketed predicate device, without requiring clinical trial data.

Device pattern: Fast-track predicate clearance. Standard predicate reliance. The short review cycle indicates strong predicate alignment - the FDA found sufficient equivalence without extended technical review.

FDA 510(k) Submission Details - K790317

510(k) Number K790317 FDA.gov
FDA Decision Cleared Substantially Equivalent - Traditional 510(k) (SESE)
Date Received February 15, 1979
Decision Date May 07, 1979
Days to Decision 81 days
Submission Type Traditional
Review Panel Chemistry (CH)
Summary -
Third-party Review No - reviewed directly by FDA
Combination Product No
PCCP Authorized No
Regulatory Context
Review time vs. panel average
8d faster than avg
Panel avg: 89d · This submission: 81d
Pathway characteristics
Predicate-based equivalence. No clinical trials required.

JFH Device Classification - Class 2, Special Controls

Product Code JFH Acid Phosphatase (prostatic), Tartrate Inhibited
Device Class Class 2 - Special Controls
CFR Regulation 21 CFR 862.1020
What this classification means

Class II devices require demonstration of substantial equivalence to a legally marketed predicate device. This pathway does not require clinical trials - it relies on engineering equivalence and performance data. Most Chemistry devices follow this clearance model.

Regulatory Peers - JFH Acid Phosphatase (prostatic), Tartrate Inhibited

All 44
Devices cleared under the same product code (JFH) and FDA review panel - the closest regulatory comparables to K790317.
PAP RIA KIT
K791735 · Nuclear Medical Systems, Inc. · Nov 1979
PAP-CHECK RIA KIT
K792043 · Serono Laboratories, Inc. · Oct 1979
RIA KIT, PROSTATIC ACID
K790580 · Monitor Science Corp. · May 1979
RIA KIT, QUANTITATION OF PROSTATIC ACID
K790817 · New England Nuclear · May 1979
P.A.P. TEST KIT, RIA-ZYME
K790040 · Mallinckrodt Critical Care · Apr 1979